Clinical trials
ER+ Breast Cancer clinical trials
Below are recruiting er+ breast cancer clinical trials, each written for real people, not researchers. We’re tracking 554 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07117630RecruitingPhase 2
A new drug combo for advanced breast cancer after standard treatment
This trial tests a new drug combination for women with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after standard treatments like CDK4/6 inhibitors and hormone therapy. It aims to see if the combination can help when other options have stopped working.
ShanghaiAges 18 years+ - NCT06874933RecruitingPhase 2
Chemo plus anlotinib and benmelstobart for HR+/HER2- breast cancer
This trial tests adding anlotinib (a targeted therapy) and benmelstobart (an immunotherapy) to standard chemotherapy before surgery for a specific type of breast cancer. It may help shrink tumors and improve outcomes for patients whose tumors have certain markers.
Hangzhou, ZhejiangAges 18–75 - NCT05728268RecruitingPhase 2
Test dose-dense chemo before surgery for high-growth hormone-positive breast cancer
This Phase 2 study tests a faster, more frequent chemotherapy schedule given before surgery (neoadjuvant therapy) for certain breast cancers that grow quickly. It may help shrink the tumor before the operation and improve treatment response in people who fit the tumor and health criteria.
Shantou, GuangdongAges 18–70 - NCT06495515RecruitingPhase 2
Dalpiciclib plus toremifene for advanced HR+ breast cancer
This trial tests a combination of two drugs (dalpiciclib and toremifene) as a first treatment for advanced breast cancer that is hormone receptor positive and HER2 negative. It may be an option if you have not had hormone therapy for advanced disease or if your cancer came back more than a year after prior treatments.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06185205RecruitingPhase 2
Accelerated high-dose radiation for early breast cancer
This trial tests a very short, high-dose radiation treatment given directly to the breast after lumpectomy. It aims to make radiation more convenient by finishing in just a few days instead of weeks, possibly with fewer side effects.
Richmond, VirginiaAges 45–79 - NCT06889610RecruitingPhase 2
Ablation plus drug therapy for advanced solid tumors
This trial tests combining a liver tumor ablation procedure with systemic drugs for people with advanced colorectal, breast, or melanoma cancer that has spread to the liver. The goal is to see if this approach can help when standard treatments have stopped working.
ShanghaiAges 18–80 - NCT06318897RecruitingPhase 2
Immunotherapy with chemo for early triple-negative breast cancer
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
Houston, TexasAges 18 years+ - NCT07402473RecruitingPhase 2
Optimizing treatment before surgery for HER2-positive breast cancer
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
Elizabeth, New JerseyAges 18–90 - NCT07400523RecruitingPhase 3
Ribociclib for breast cancer with leftover disease after chemo
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
Zhanjiang, GuangdongAges 18 years+ - NCT05878314Recruiting
Testing how hormones and tumor markers guide breast cancer treatment
This study looks at how planned hormone (endocrine) treatment, the menstrual cycle, and lab markers from the tumor may help doctors choose the best treatment for early-stage, hormone-receptor–positive, HER2-negative breast cancer. It may help personalize decisions, including what to do before surgery.
TübingenAges 18 years+ - NCT06500208RecruitingPhase 2
Adebrelimab plus chemo before surgery for high-risk breast cancer
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy before surgery for people with high-risk, hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this approach can shrink tumors more effectively than chemotherapy alone.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06727487Recruiting
Ovarian suppression and exercise in young breast cancer patients
This trial tests whether adding a supervised exercise program helps women with hormone-positive breast cancer who are receiving ovarian suppression therapy. It looks at how exercise affects treatment side effects, quality of life, and long-term health.
MadridAges 18–45 - NCT04020575RecruitingPhase 1
CAR T cells made from your blood for advanced breast cancer
This Phase 1 trial tests CAR T cells made from your own immune cells to target advanced breast cancer. The cells are designed to recognize a specific cancer marker (called MUC1*), with the goal of shrinking tumors or keeping them under control.
Duarte, CaliforniaAges 18 years+ - NCT07469267Recruiting
Armpit radiation vs more surgery for early breast cancer with node spread
This trial tests whether radiation to the lower armpit (level I-II axilla) works as well as more extensive surgery for women with early-stage breast cancer that has spread to one or two sentinel lymph nodes (with cancer size > 2 mm). It aims to find a gentler treatment that still keeps the cancer from coming back.
Guiyang, GuizhouAges 18 years+ - NCT07395336RecruitingPhase 2
Elacestrant and exemestane for HR+/HER2- breast cancer that has spread
This trial tests combining elacestrant (a new hormone therapy) with exemestane (a standard hormone therapy) for people whose HR+/HER2- breast cancer has spread and who have already tried a CDK4/6 inhibitor with anastrozole or letrozole. It may help if your tumor shows certain activity on a special PET scan.
Milan, ItalyAges 18 years+ - NCT07244094Recruiting
AI predicts breast cancer spread risk from tissue scans
This trial uses artificial intelligence to analyze images of your tumor tissue to predict if breast cancer might spread to other parts of the body. It may help doctors better understand your individual risk and guide treatment decisions.
Changchun, JilinAges 18–95 - NCT06837792RecruitingPhase 2
T-DXd vs hormone therapy for HER2-low advanced breast cancer
This trial compares a targeted antibody-drug conjugate called T-DXd against standard hormone therapy for women with HR+, HER2-low advanced breast cancer that has progressed after first-line endocrine therapy plus a CDK4/6 inhibitor. It aims to see if T-DXd works better than continuing hormone therapy alone.
SeoulAges 19 years+ - NCT04874064Recruiting
AI blood tests for triple-negative breast cancer after treatment
This study uses a computer (AI) to read results from blood tests to look for signs of remaining triple-negative breast cancer, before and/or after surgery. It may help doctors better detect residual tumor and guide follow-up care.
London, OntarioAges 18 years+ - NCT05634889Recruiting
Personalized breast radiation for limited lymph-node spread
This trial studies a tailored form of radiation treatment for some people with early breast cancer whose sentinel lymph-node biopsy shows cancer in 1–2 nodes. It may help improve local control while guiding the best radiation approach for your specific situation.
HelsinkiAges 18 years+ - NCT07287098RecruitingPhase 2
Imlunestrant for premenopausal women with ER+/HER2- early breast cancer
This trial tests a new hormone-blocking pill (imlunestrant) in premenopausal women with early-stage ER+/HER2- breast cancer. Depending on whether you've had prior hormone therapy, the study will see if this treatment works better than standard options.
Birmingham, AlabamaAges 18 years+ - NCT04480203Recruiting
Digital coping tools after new breast cancer diagnosis
This trial tests two online programs designed to help people cope after being diagnosed with breast cancer. It may help you manage stress and emotions during treatment or recovery.
OsloAges 20–69 - NCT05904964RecruitingPhase 3
Targeted drug for hormone-positive, HER2-low metastatic breast cancer
This Phase 3 trial tests disitamab vedotin (a targeted drug) in people with hormone receptor–positive, HER2-low metastatic breast cancer that can’t be cured with surgery or radiation. It aims to see whether the drug can control the cancer better than current standard care.
Guangzhou, GuangdongAges 18–70 - NCT06185569Recruiting
French study on outcomes in HR+/HER2- early breast cancer patients with Oncotype DX
This study looks at how well treatments work for people with early-stage, hormone receptor-positive, HER2-negative breast cancer when the Oncotype DX test helps guide therapy. It aims to understand real-world outcomes in French patients.
BesançonAges 18 years+ - NCT05999149RecruitingPhase 3
Famitinib plus chemo and immunotherapy before breast cancer surgery
This trial tests whether adding a targeted therapy pill (famitinib) to standard chemo plus an immunotherapy (camrelizumab) can shrink triple negative breast cancer before surgery. It may help people with earlier-stage disease who have not had certain prior treatments.
Shanghai, Shanghai MunicipalityAges 18–70
Hear when a new ER+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for er+ breast cancer?
- Yes. Clin2 currently lists 554 recruiting er+ breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a er+ breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a er+ breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.